Given that there are currently no clear recommendations regarding therapeutic options for rituximab refractory/relapsed follicular lymphoma patients, this study aimed to describe the real-life management of patients with refractory follicular lymphoma after systemic rituximab-containing regimens (rFL), and rFL patient characteristics. In this retrospective, national, multicentre study, descriptive analyses were mainly performed according to rituximab-containing regimen at rFL diagnosis [rituximab monotherapy (R-MONO), rituximab + chemotherapy (R-COMBO), and ongoing rituximab maintenance (R-MAINTAIN)]. The 459 analysed patients experienced rituximab-refractoriness between October 2013 and September 2015: R-MONO: 58 (13%), R-COMBO: 197 (43%), R-MAIN-TAIN: 204 (44%). Post-refractoriness strategies were heterogeneous: idelalisib AE rituximab (22%), without anti-lymphoma treatment (21%), rituximab-chemotherapy (21%) and stem cell transplantation (18%). Rituximab was continued in combination in 41% of cases. Chosen strategies varied according to patient age (without anti-lymphoma treatment: 28% of patients if ≥65 years vs. 12% if <65 years old; stem-cell transplantation: 4% vs. 38%), treatment line at rFL, FL International Prognostic Index score and prior treatment. This French retrospective study, the first one conducted in a large cohort of rFL patients, showed that further strategies were highly heterogeneous, depending notably on patient characteristics and previous treatment. These data are the basis for a better understanding of rFL management and for the design of clinical trials in these patients.
Follicular lymphoma (FL) is the second most frequent subtype of non-Hodgkin lymphoma in Western Europe, and its annual incidence has rapidly increased during recent decades to recently reach 5-7/10 000 (Dreyling et al, 2014) . Considering the indolent evolution of this B-cell lymphoma, with a median survival close to 10 years, 2530 new FL patients were estimated in 2012 in France (Monnereau et al, 2013a) .
Apart from some FL patients initially managed with watchful waiting, most patients need systemic cytotoxicbased treatment. On the basis of previous randomized studies (Hiddemann et al, 2005; Marcus et al, 2005; Herold et al, 2007; Salles et al, 2008) , the combination of rituximab (R), an anti-CD20 monoclonal antibody, with various chemotherapy regimens is now regarded as the standard of care in FL first-line therapy. At first diagnosis, the therapeutic strategy varies according to patient and disease characteristics: management without anti-lymphoma treatment or R alone, if low tumour burden, R-containing chemotherapy regimens, such as R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisolone), R-CVP (rituximab, cyclophosphamide, vincristine, prednisolone) or R-bendamustine, and even with stem-cell transplantation (SCT) if high tumour burden. After first-line treatment, R maintenance therapy was also shown to improve progression-free survival (PFS) in FL patients compared to watchful waiting (3-year PFS: 75% vs. 58%) (Salles et al, 2011) .
In current European and US guidelines published in 2014 and 2015 respectively (Dreyling et al, 2014; Hoppe et al, 2015) , there are no clear recommendations to choose between available therapeutic options for refractory/relapsed FL patients, besides the fact that further treatment has to be adapted to previous therapy and to patient and disease characteristics. Furthermore, few data are available regarding the real-life management of patients with refractory/relapsed FL after systemic R-containing regimens, and the characteristics of such patients.
In this context, this study primarily aimed to describe in routine clinical practice, at a given time, the management of FL patients after R-refractoriness FL (rFL), i.e. during an Rcontaining regimen or within the following 6 months, and the characteristics of such patients. Secondary objectives included the same descriptions according to three patients' groups defined by the ongoing R-containing regimen at the time of rFL [R monotherapy (R-MONO patients), R combined with chemotherapy (R-COMBO patients), and ongoing R maintenance (R-MAINTAIN patients)], and the identification of the decision-making factors of the medical strategy set up after rFL diagnosis.
Methods
This French non-interventional, multicentre, retrospective study was managed in cooperation with a scientific committee of two haematologists. Patients were informed by their physicians about their participation in the study.
Recruitment of physicians and patients
Specialists that treated adult FL patients with R-refractoriness between October 2013 and September 2015 were recruited from all over mainland France. R-refractoriness was defined as disease progression after at least one full R dose (375 mg/m 2 ), no clinical response after at least 4 weekly doses of R-MONO or at least 4 cycles of R-COMBO, or relapse (after reaching a significant clinical response) within 6 months after at least 4 weekly doses of R-MONO or at least 4 cycles of R-COMBO. R-refractoriness was considered after or during the first, second or third line of treatment. Patients with histological transformation at the most recent biopsy were excluded. For patients who experienced several R-resistant relapses during the study period, only the first one was considered.
Data collection
The specialty, medical facility and geographic location of participant specialists were collected. On the basis of a chart review, physicians reported data on patients, FL and rFL characteristics, treatment lines prior to rFL and therapeutic strategy set up after rFL diagnosis. Quality controls were performed during on-site visits at all participating centres, and via an internal data consistency review by the scientific committee of 10% of the completed case report forms (random selection).
Study size and statistical methods
For this descriptive study, a minimum of 220 included patients would allow the proportion of patients with a given therapeutic strategy after rFL diagnosis to be described, with an absolute precision of AE7%. Most of the analyses were descriptive and performed in the whole population of patients who met the selection criteria, as well as in subgroups (R-MONO, R-COMBO and R-MAINTAIN) and according to patient and disease characteristics. To search for decision-making factors of the therapeutic strategies set up after rFL diagnosis, multinomial logistic regressions (Hosmer & Lemeshow, 1989) 
Results

Participating physicians and patients
Among the 97 French specialists solicited throughout France for study participation, 68 (70%; 37 haematologists, 19 onco-haematologists, 9 oncologists and 3 other specialists) included at least one eligible patient (mean 6Á8 inclusions per physician; range: 1-20). Among the 480 included patients, 459 patients fulfilled all the selection criteria [58 patients (13%) in the R- MONO group, 197 (43%) in the R-COMBO group and 204 (44%) in the R-MAINTAIN group]. In the R-MAINTAIN group, maintenance was implemented after induction with rituximab in combination with chemotherapy for 174 patients (85%), rituximab monotherapy (n = 16, 8%) and rituximab plus idelalisib (n = 1, 1%), and after stem-cell transplantation for 13 patients (6%). The 21 patients excluded from analysis experienced rFL outside the allowed time interval (between 1 October 2013 and 30 September 2015) or more than 6 months after the last R-containing regimen administration.
Patient characteristics at rFL diagnosis
At the time of rFL diagnosis, the majority of the 459 patients were followed in public hospitals (university or regional hospitals: 44%; other hospitals: 30%) and by haematologists or onco-haematologists (85%).
Patient characteristics at rFL diagnosis are detailed in Table I . In the whole population, 60% of patients were at P. Solal-C eligny et al Table I . Characteristics of patients at the time of rFL diagnosis* (n = 459).
Patients' characteristics Age (years) Mean AE SD 68Á9 AE 13Á2 7 0 Á3 AE 11Á8 7 2 Á8 AE 12Á7 6 6 Á7 AE 11Á9 ≥65 years, n (%)
41 ( ECOG, Eastern Cooperative Oncology Group; FL, follicular lymphoma; FLIPI, Follicular Lymphoma International Prognostic Index; Q1-Q3, interquartile range; R-COMBO, refractory to rituximab + chemotherapy; R-MAINTAIN, refractory to ongoing rituximab maintenance; R-MONO, refractory to rituximab monotherapy; R, rituximab; rFL, follicular lymphoma refractory to rituximab; SCT, stem cell transplantation, SD, standard deviation. *Refractoriness during the last R-containing regimen or within the following 6 months. †Unfavourable factors: patient age >60 years, lactate dehydrogenase >upper limit of normal, ECOG performance status ≥2, Ann-Arbor stage III or IV, more than one extra-nodal site.
least 65 years of age although this proportion varied according to prior FL therapy: 71% of the R-MONO patients were aged 65 or over (versus 58% of R-COMBO and R-MAIN-TAIN patients). On the other hand, the median time between initial FL diagnosis and studied rFL (Table I) Table I ). At rFL diagnosis, the ongoing R-containing regimen was the first-line of FL treatment in 27%, 65% and 71% of the R-COMBO, R-MAINTAIN and R-MONO patients, respectively (Table I) . At this time, the most common chemotherapy regimens combined with R were CHOP or mini-CHOP (cyclophosphamide + adriamycin + vincristine + prednisone; 35%), bendamustine (24%), CVP (11%), and DHAP (dexamethasone + cytarabine + cisplatin) or mini-DHAP or DHAC (dexamethasone + doxorubicin + cytarabine + carboplatin) (8%).
Therapeutic management of patients after rFL diagnosis
Post-rFL therapies according to patient and disease characteristics in the whole population. The therapeutic strategies decided after rFL diagnosis for the whole population are presented in Fig 1. Induction treatments used were conformed to the decisions of the centre's multidisciplinary meeting in 98% of cases.
Patients of at least 65 years of age were managed without anti-lymphoma treatment (watchful waiting or best supportive care) after rFL diagnosis more often than younger patients (28% vs. 12%), particularly if they had a FLIPI score of 3 (33% vs. 11% in <65 years). Conversely, patients under 65 years of age were transplanted more often (38% vs. 4%), particularly if they had a FLIPI score of 3 at rFL diagnosis (46% vs. 8%). Thirty-three percent (n = 7) of the younger patients with low FLIPI (0-1) were managed without antilymphoma treatment.
When rFL was diagnosed after the second or third line of treatment, idelalisib (AER) was the most frequently post-rFL strategy (in 38% of the patients). In these patients, R-chemotherapy was less prescribed than in patients with rFL at first line (10% vs. 32%) as well as SCT (12% vs. 24%). Whatever the treatment line at rFL diagnosis, bendamustine was prescribed in 28% of the 358 patients having received induction treatment after rFL diagnosis and in 10% as monotherapy. In addition, in this rFL population, R-treatment was continued, combined with another agent, in 41% of the cases.
Post-rFL therapies according to the previous R-containing regimen. The therapeutic strategies set up after rFL also varied according to the R-containing regimen at rFL diagnosis (Fig 1) . The majority of the 58 R-MONO patients received R-COMBO (36%) or were managed without anti-lymphoma treatment (26%), whereas idelalisib (AER) was less frequently used (14%). Furthermore, no SCT was performed among the 41 R-MONO patients having experienced rFL at first-line therapy, while 13 of them (32%) were managed without anti-lymphoma treatment. Idelalisib (AER) was the most frequent strategy (36%) among the 17 R-MONO patients with second or third line therapy at rFL diagnosis. Among the 197 R-COMBO patients, 33% received treatment with idelalisib AER (n = 65), 22% were managed without anti-lymphoma Therapeutic management of patients after rFL diagnosis, according to prior FL therapy (study primary endpoint). FL, follicular lymphoma; R-COMBO, refractory to rituximab + chemotherapy; R-MAINTAIN, refractory to ongoing rituximab maintenance; R-MONO, refractory to rituximab monotherapy; R, rituximab; rFL, follicular lymphoma refractory to rituximab. treatment (n = 43), and 17% underwent SCT (n = 33) (Table II) . Among the 54 R-COMBO patients having experienced rFL at first-line therapy, an additional chemotherapy regimen (combined with R or not) was prescribed in 24 (44%). For the 204 R-MAINTAIN patients, less marked differences were observed between post-rFL strategies (Table II) . However, among the 132 R-MAINTAIN patients who experienced rFL at first-line therapy, SCT (n = 41, 31%) and Rchemotherapy (n = 38, 29%) were the most used post-rFL strategies.
Decision-making factors of the post-rFL strategies. Using multinomial regressions, the main factors that might influence the choice of the post-rFL strategy were the number of treatment lines at rFL diagnosis, the specialty of the physician in charge of patient follow-up and patient age (Table III) . In particular, compared to the post-rFL prescription of an R-chemotherapy regimen, the patients with rFL diagnosis after the second or third line treatment (versus after first line) were more than 23 times more likely to receive idelalisib (AER) therapy. To a lesser extent, patient ECOG and FLIPI score at rFL diagnosis also impacted this choice (for example, an ECOG performance score >2 increased the probability to be managed without antilymphoma treatment by more than 21-fold). In addition, SCT was strongly favoured in younger patients (10-fold more if <65 years compared to older patients) and it was associated with high risk according to FLIPI (score of 3); chemotherapy alone was less prescribed in patients at FLIPI high risk but preferred in patients after the second or third line of treatment; management without antilymphoma treatment was preferred in patients in poorer general health (ECOG performance score >2) and in those with rFL after the second or third line of treatment. A sensitivity analysis with chemotherapy alone as reference treatment did not impact the interpretation of the results. Table II . Therapeutic management of patients after rFL diagnosis, according to patients and disease characteristics -R-COMBO patients (n = 197) and R-MAINTAIN patients (n = 204).
Stem cell transplantation Idelalisib AE R R-Chemotherapy Chemotherapy
Management without anti-lymphoma treatment Other n = 33 n = 65 n = 30 n = 17 n = 43 n = 9 R-COMBO patients (n = 197) Therapeutic strategy according to patient age, n (%) <65 years (n = 83) 28 (33Á7) 29 (34Á9) 12 (14Á5) 5 (6Á0) 7 (8Á4) 2 (2Á4) ≥65 years (n = 114) 5 (4Á4) 36 (31Á6) 18 (15Á8) 12 (10Á5) 36 (31Á6) 7 (6Á1) Therapeutic strategy according to number of treatment lines at rFL diagnosis, n (%) 1st line (n = 54) 13 (24Á1) 4 (7Á4) 15 (27Á8) 9 (16Á7) 12 (22Á2) 1 (1Á9) 2nd or 3rd line (n = 143) 20 (14Á0) 61 (42Á7) 15 (10Á5) 8 (5Á6) 31 (21Á7) 8 (5Á6) Therapeutic strategy according to the patient age and number of treatment lines at rFL diagnosis, n (%) <65 years 1st line (n = 24)
R-MAINTAIN patients (n = 204) Therapeutic strategy according to patient age, n (%) 
Discussion
No clear recommendations are given by the currently available guidelines for the therapeutic management of refractory/ relapsed FL patients (Dreyling et al, 2014; Hoppe et al, 2015) , and few epidemiological data are available on the management of this patient population. Given that rituximab is a component of the standard treatment for FL patients, this French retrospective study aimed to describe, in a reallife setting, the therapeutic strategies set up after refractoriness to rituximab and their decision-making factors, on the basis of patient and disease characteristics at rFL diagnosis. The study showed that at the time of the refractoriness diagnosis, the majority of the analysed patients had received R-COMBO or R-MAINTAIN therapy. The post-rFL therapeutic strategies were highly heterogeneous. If this variety was explained by the lack of precise recommended strategies in such patients, only 10% of those receiving post-rFL induction received monotherapy with bendamustine, one of the agents approved for refractory non-Hodgkin lymphomas in France. In the other hand, in rFL patients, physicians decided to continue rituximab, combined with another agent, in 41% of the cases. Although there are no clinical data to support this policy, this may be related to in vitro data suggesting synergistic effects between R and various cytotoxic agents (Di Gaetano et al, 2001) .
Regarding SCT, a retrospective study conducted with a minimum follow-up of 12 years in 121 transplanted FL patients (Rohatiner et al, 2007) showed that beneficial effects of SCT were observed if performed no later than the second relapse. In our study, SCT was done more often when rFL was diagnosed at first line of treatment but other patient characteristics favoured this therapeutic option, such as patient age (<65 years) and FLIPI high-risk disease at rFL diagnosis.
A noticeable proportion of patients (21%) were managed without anti-lymphoma treatment after rFL, especially for the oldest when they were at higher risk.
In accordance with the current recommendations regarding refractory/relapsed FL patients, the post-rFL therapeutic options mainly depended on the characteristics of the patients (age and ECOG performance score) and the disease (line of treatment and FLIPI score) at rFL diagnosis. The therapeutic option appears to be chosen on a case-by-case basis, and physicians take into account disease history and previous FL treatment, as well as the general status of the patient at the time of rFL diagnosis. However, no-treatment policy could be either a watchful waiting until more clinically meaningful evolution or stopping of anti-lymphoma treatment for best supportive care, and the data collected in our study did not allow these options to be differentiated.
That being said, this study is the first to be conducted in a large cohort of rFL patients, with analyses carried out in patient groups defined according to prior FL treatment (R-MONO, R-COMBO and R-MAINTAIN). The high number of patients included allowed a higher precision than initially expected, resulting in more robust results. Even if selection and information biases inherent to such an observational and retrospective study cannot be totally excluded, data quality controls and published literature (Monnereau et al, 2013b; Mounier et al, 2015) support the generalizability of our results.
Data collected for this study covered the period between October 2013 and September 2015. Indeed, the noticeable proportion of rFL patients treated with idelalisib as postrFL therapy probably shows that physicians tend to prescribe new treatments as soon as they become available, especially in such an incurable setting. As a result, the heterogeneity of post-rFL therapeutic strategies as observed in this French study makes it difficult to conduct clinical trials assessing new treatments in comparison with a consensual comparator and to refine the current recommendations for rFL patients' management. In this context, the interest of this study conducted in a real-life setting is to provide a snapshot at a given time-point. Considering new expected treatments for FL patients, such as anti-BCL2 and new anti-CD20 antibodies, as well as recent cautions concerning idelalisib treatment (Cheah & Fowler, 2016) , the data from this study are the basis needed for the followup of further therapeutic strategies for rFL patients in routine clinical practice.
